Trial Search Results
Labor and Delivery Implant Insertion: A Randomized Controlled Trial
A barrier to initiating progestin contraceptives in the early postpartum period is the concern of interference with breastfeeding, specifically lactogenesis. In this trial, the investigators aim to describe the effects of immediate insertion of the contraceptive implant on breastfeeding. The investigators seek to examine the time to lactogenesis with immediate post-delivery insertion in delivery room versus insertion of a contraceptive implant in the postpartum ward prior to medical discharge. For this study, 82 consenting women will be randomized to immediate implant insertion (0-2 hours following delivery) in the delivery room or insertion of the implant following delivery in postpartum room and prior to medical discharge (24-48 hours following delivery).
Participants complete a questionnaire that asks questions about breastfeeding continuation, supplementation, duration, and exclusivity. This questionnaire also includes questions about contraceptive continuation, patient satisfaction with implant, pregnancy, and postpartum care visits.
Stanford is currently not accepting patients for this trial.
- Drug: Etonogestrel-Immediate
- Drug: Etonogestrel-Delayed
- Pregnant women who are patients of the Stanford University Obstetrics service
- Pregnant women who delivery a healthy infant, regardless of gestational age.
- Intend to breastfeed
- Desire the contraceptive implant as their method of contraception
- Agree to be randomized to delivery room vs. postpartum ward insertion
- Not English or Spanish speaking
- Allergy or Contraindication to contraceptive implant.
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study